期刊文献+

2型糖尿病伴非酒精性脂肪肝患者胰岛素抵抗与游离脂肪酸关系研究 被引量:4

Relationship between insulin resistance and free fatty acids in patients of type two diabetes mellitus with non-alcoholic fatty liver disease(NAFLD)
下载PDF
导出
摘要 目的:了解2型糖尿病伴非酒精性脂肪肝(NAFLD)患者胰岛素抵抗(IR)与游离脂肪酸(FFA)的关系。方法:2型糖尿病伴非酒精性脂肪肝患者39例、单纯2型糖尿病患者42例、单纯非酒精性脂肪肝患者40例、健康人群42例为研究对象。检测所有对象的FFA、胰岛素敏感性指数(ISI)以及总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)等指标。结果:2型糖尿病伴非酒精性脂肪肝组的FFA、ISI、TC、TG和LDL-C分别为(697.58±45.12)μmol/L,-4.99±0.12,(6.72±1.26)、(3.14±0.98)、(3.56±0.99)mmol/L;FFA、TC、TG、LDL-C等各项指标均以2型糖尿病伴非酒精性脂肪肝组高于其余各组(均P<0.05);ISI则以2型糖尿病伴非酒精性脂肪肝组低于其余各组(均P<0.05);将2型糖尿病伴非酒精性脂肪肝组的FFA与ISI、血脂3项指标作相关性分析。结果显示,FFA与ISI呈负相关(r=-0.773,P<0.05),与TC、TG、LDL-C呈正相关(分别为r=0.791,0.816,0.873,均P<0.05)。结论:在2型糖尿病伴非酒精性脂肪肝中,FFA升高与IR是并存的,并且存在明显相关关系,二者在疾病的发生发展中均具有重要的作用。 Objective: To explore the relaionship between insulin resistance(IR) and free fatty acids(FFA) in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD).Methods:The patients of type 2 diabetes mellitus with NAFLD (39 cases),type 2 diabetes alone (42 cases), NAFLD alone (40 eases) were selected as case groups,while the healthy individuals(42 cases) were selected as control group.FFA,insulin-sensitivity index(ISI),total cholesterol(TC),low density lipoprotein-cholesterol (LDL-C) were tested for each subject.Results:The levels of FFA,ISI,TC,TG and LDL-C of type two diabetes mellitus CHD were (697.58±45.12)μmol/L,-4.99±0.12,(6.72±1.26) mmol/L,(3.14±0.98)mmol/L,(3.56±0.99) mmol/L,respectively.The levels of FFA,TC,TG,LDL-C of the type two diabetes mellitus companied with CHD group were higher than those of other three groups (P〈0.05).However,ISI level of former group was lower than that of other three group (all P〈0.05).According to the type 2 diabetes mellitus with NAFLD group,there existed negative correlation between FFA and ISI(r=-0.773,P〈0.05),while there existed positive correlation between FFA and TC,TG,LSL-C(r=-0.791,0.816,0.873, all P〈0.05).Conclusion:In patients of type 2 diabetes mellitus with NAFLD,there existed clear correlation between higher FFA and more IR.Both factors play a very important role in the development of the disease.
出处 《中国医药导报》 CAS 2008年第16期50-52,共3页 China Medical Herald
关键词 2型糖尿病 非酒精性脂肪肝 胰岛素抵抗 游离脂肪酸 Type 2 diabetes mellitus Non-alcoholic fatty liver disease(NAFLD) Insulin resistance(IR) Free fatty acids(FFA)
  • 相关文献

参考文献9

  • 1[1]Marchesini G,Brizi M,Bianchi G,et al.Nonalcoholic fatty liver disease:a feature of the metabolic syndrome[J].Diabetes,2001,50(8):1844-1850.
  • 2[2]Bugianesi E,Gastaldelli A.Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease:sites and mechanisms[J].Dia-betologia,2005,48(4):634-642.
  • 3Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量:1515
  • 4李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2126
  • 5[6]Tang Y,Osawa H,Onuma H,et al.Phosphodiesterase3B gene expression is enhanced in the but adipose tissue of obese insulin resistance dh/db mouse[J].Betes Res Clin Pract,2001,54,(3):145-155.
  • 6[7]Tripathy D,Mohanty P,Dhindsa S,et al.Elevation of free fatty acids in-duces inflammation and impairs vascular reactivity inhealthy subjrcts[J].Diabetes,2003,52(12):2882-2887.
  • 7[8]Burke JR.Targeting I kappa B kinase for the trestment of inflammatory and other diserders[J].Curr Opin Drug Discov Devel,2003,6(5):720-728.
  • 8[9]Sun Y,Liu S.Phosphoenolpyruvate carboxykinase overexpression selec-tively attenuates insulin signaling and hepatic insulin sensitivity in transgeic mice[J].J Bid Chem,2002,277(26):23301-23307.
  • 9刘蓉,严祥,何津春,刘永铭.非酒精性脂肪肝血浆抵抗素与肥胖和胰岛素抵抗关系的研究[J].中国实用内科杂志,2006,26(9):1333-1336. 被引量:17

二级参考文献26

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-649.
  • 3Neuschwander Tetri BA,Caldwell SH.Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference.Hepatology,2003,37:1202-1219.
  • 4Angulo P.Nonalcoholic fatty liver disease.N Engl J Med,2002,346:1221-1231.
  • 5Ghali P,Lindor KD.Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.Semin Liver Dis,2004,24:389-397.
  • 6Harrison SA,Torgerson S,Hayashi P,et al.Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003,98:2485-2490.
  • 7Angulo P.Use of ursodeoxycholic acid in patients with liver disease.Curr Gastroenterol Rep,2002,4:37-44.
  • 8Agrawal S,Bonkovsky HL.Management of nonalcoholic steatohepatitis:an analytic review.J Clin Gastroenterol,2002,35:253-261.
  • 9Comar KM,Sterling RK.Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacal Ther,2006,23:207-215.
  • 10Lok AS,McMahon B J; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.

共引文献3639

同被引文献28

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部